Premium
Disseminated A canthamoeba infection in a heart transplant recipient treated successfully with a miltefosine‐containing regimen: Case report and review of the literature
Author(s) -
Brondfield Max N.,
Reid Michael J.A.,
Rutishauser Rachel L.,
Cope Jennifer R.,
Tang Jevon,
Ritter Jana M.,
Matanock Almea,
Ali Ibne,
Doernberg Sarah B.,
HiltsHoreczko Alexandra,
DeMarco Teresa,
Klein Liviu,
Babik Jennifer M.
Publication year - 2017
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12661
Subject(s) - miltefosine , medicine , immunosuppression , regimen , heart transplantation , fluconazole , transplantation , immunology , dermatology , antifungal , leishmaniasis , visceral leishmaniasis
Disseminated acanthamoebiasis is a rare, often fatal, infection most commonly affecting immunocompromised patients. We report a case involving sinuses, skin, and bone in a 60‐year‐old woman 5 months after heart transplantation. She improved with a combination of flucytosine, fluconazole, miltefosine, and decreased immunosuppression. To our knowledge, this is the first case of successfully treated disseminated acanthamoebiasis in a heart transplant recipient and only the second successful use of miltefosine for this infection among solid organ transplant recipients. A canthamoeba infection should be considered in transplant recipients with evidence of skin, central nervous system, and sinus infections that are unresponsive to antibiotics. Miltefosine may represent an effective component of a multidrug therapeutic regimen for the treatment of this amoebic infection.